Purchase this article with an account.
Aki Kato, Ari Shinojima, Miki Sawa, Tetsuju Sekiryu, Yuji Oshima, Ryusaburo Mori, Mitsuko Yuzawa, Yuichiro Ogura, Tatsuro Ishibashi, Tsutomu Yasukawa; A Multicenter Randomized Controlled Study of Antioxidant Supplementation with Lutein for the Treatment of Chronic Central Serous Chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):167.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Chronic central serous chorioretinopathy (CSC) has persistent serous retinal detachment, resulting in gradual vision loss. The purpose of this study is to investigate the functional and morphological changes in patients with chronic CSC after antioxidant supplementation with lutein.<br />
This study is a multicenter, double-masked, randomized, placebo-controlled trial of antioxidant supplementation with lutein in 100 eyes of 100 patients who diagnosed chronic CSC. The patients were randomly divided into two groups, taking tablets with antioxidants and lutein or placebo for 6 months. The formulation of supplements contains 15 mg of lutein, 288 mg of vitamin C, 150 mg of vitamin E, 9 mg of zinc, and 1.2 mg of copper as a total daily dosage. The best-corrected visual acuities (BCVAs) and the thickness of subfoveal fluid on optical coherence tomography (OCT) were measured at baseline and in months 1, 3 and 6.<br />
Seventy nine patients (37 patients of supplementation group and 42 patients of placebo group) completed 6-month followed-up. In supplementation group, mean BCVA in the LogMAR unit was significantly improved from 0.16 ± 0.27 at baseline to 0.09 ± 0.22 in month 6 (p=0.003). In placebo group, mean BCVA was changed from 0.09 ± 0.24 at baseline to 0.08 ± 0.24 in month 6 (p=0.589).<br /> The percentages of eyes with remission of subfoveal fluid were 20.0% in month 3 and 32.4% in month 6 in supplementation group, and 9.5% and 28.6% in placebo group, respectively, while there were no significant differences between both groups. Mean reduction rate of the thickness of subfoveal fluid was 0.71 in supplementation group, significantly decreased as compared with the baseline (p=0.028), while it was 0.97 in placebo group (p=0.898).<br />
In the current study, the remission of subfoveal fluid was observed approximately 30% of eyes in month 6 in both groups, while mean BCVA and mean thickness of subfoveal fluid were significantly improved only in supplementation group as compared with the baseline. Further studies are needed to evaluate the long-term impacts of antioxidant supplementation with lutein for chronic CSC.
This PDF is available to Subscribers Only